Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors por Sung-Hyun Kim, Hari Menon, Saengsuree Jootar, Tapan Saikia, Jae-Yong Kwak, Sang-Kyun Sohn, Joon Seong Park, Seong Hyun Jeong, Hyeoung Joon Kim, Yeo-Kyeoung Kim, Suk Joong Oh, Hawk Kim, Dae Young Zang, Joo Seop Chung, Ho Jin Shin, Young Rok Do, Jeong-A Kim, Dae-Young Kim, Chul Won Choi, Sahee Park, Hye Lin Park, Gong Yeal Lee, Dae Jin Cho, Jae Soo Shin, Dong-Wook Kim

Ligazón do recurso